Zkusit zdarma
Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc.

AVIR
Cena:
$ 4.42
+0.18 (4.25%)
Valuace
70
Růst
0
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround

10:37 15-05-2026

Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion o...

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

7:00 13-05-2026

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company)...

Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript

0:30 13-05-2026

Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript...

Atea Pharmaceuticals Q1 Earnings Call Highlights

Atea Pharmaceuticals Q1 Earnings Call Highlights

18:08 12-05-2026

Atea Pharmaceuticals NASDAQ: AVIR said it remains on track for two key Phase 3 hepatitis C readouts ...

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

16:05 12-05-2026

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with...

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

7:00 05-05-2026

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company)...

Atea Pharmaceuticals (NASDAQ:AVIR) vs. Trevi Therapeutics (NASDAQ:TRVI) Financial Survey

Atea Pharmaceuticals (NASDAQ:AVIR) vs. Trevi Therapeutics (NASDAQ:TRVI) Financial Survey

2:08 12-03-2026

Trevi Therapeutics (NASDAQ: TRVI - Get Free Report) and Atea Pharmaceuticals (NASDAQ: AVIR - Get Fre...

Atea Pharmaceuticals Q4 Earnings Call Highlights

Atea Pharmaceuticals Q4 Earnings Call Highlights

4:48 07-03-2026

Atea Pharmaceuticals (NASDAQ: AVIR) outlined progress in its hepatitis C (HCV) late-stage developmen...

Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript

18:55 05-03-2026

Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript...

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

16:05 05-03-2026

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Result...

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

7:00 24-02-2026

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus  Initiation of Ph...

BML Capital Management LLC Cuts Holdings in Atea Pharmaceuticals, Inc. $AVIR

BML Capital Management LLC Cuts Holdings in Atea Pharmaceuticals, Inc. $AVIR

4:22 23-02-2026

BML Capital Management LLC lessened its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ: AV...

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

13:55 15-01-2026

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcri...

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4% – Here’s What Happened

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4% – Here’s What Happened

1:33 31-12-2025

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR - Get Free Report) was down 1.4% during mid-day trading on ...

Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026

Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026

5:51 23-12-2025

Atea Pharmaceuticals (AVIR) offers a late-stage, best-in-class HCV cure, with significant upside, cu...

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

7:00 22-12-2025

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in U...

Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript

Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript

14:31 13-11-2025

Atea Pharmaceuticals, Inc. ( AVIR ) Discusses Next-Generation Hepatitis C Treatment Developments and...

Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

19:01 12-11-2025

Atea Pharmaceuticals, Inc. ( AVIR ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Part...

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

16:05 12-11-2025

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topl...

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

7:00 05-11-2025

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company...

close

ATEA PHARMACEUTICALS TO HIGHLIGHT 2026 STRATEGIC PRIORITIES AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

08-01-2026
PHASE 3 TOPLINE RESULTS FOR POTENTIAL BEST-IN-CLASS REGIMEN FOR TREATMENT OF HCV ON TRACK FOR 2026 T...
Více zde

ATEA PHARMACEUTICALS TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

06-01-2026
BOSTON, JAN. 06, 2026 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY...
Více zde

ATEA PHARMACEUTICALS COMPLETES PATIENT ENROLLMENT IN NORTH AMERICAN PHASE 3 TRIAL EVALUATING REGIMEN OF BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS

22-12-2025
ENROLLMENT COMPLETED IN C-BEYOND PHASE 3 TRIAL WITH MORE THAN 880 HCV TREATMENT-NAÏVE PATIENTS IN U...
Více zde

ATEA PHARMACEUTICALS TO PRESENT AT THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

19-11-2025
BOSTON, NOV. 19, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY...
Více zde

ATEA PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

12-11-2025
PATIENT ENROLLMENT ON TRACK IN GLOBAL PHASE 3 PROGRAM FOR TREATMENT OF HEPATITIS C VIRUS (HCV), TOPL...
Více zde

ATEA PHARMACEUTICALS PRESENTS NEW DATA SUPPORTING THE FIXED-DOSE COMBINATION OF BEMNIFOSBUVIR AND RUZASVIR AS A POTENTIAL BEST-IN-CLASS REGIMEN FOR TREATMENT OF HEPATITIS C VIRUS INFECTION AT THE LIVER MEETING® 2025

07-11-2025
COMPANY HOSTING VIRTUAL KOL PANEL EVENT THURSDAY, NOVEMBER 13TH AT 10:00 AM ET COMPANY HOSTING VIRTU...
Více zde

ATEA PHARMACEUTICALS TO HOST THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE CONFERENCE CALL ON NOVEMBER 12, 2025

05-11-2025
BOSTON, NOV. 05, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY...
Více zde

ATEA PHARMACEUTICALS TO HOST VIRTUAL HCV KOL PANEL EVENT ON NOVEMBER 13, 2025

22-10-2025
BOSTON, OCT. 22, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY...
Více zde

ATEA PHARMACEUTICALS TO PRESENT NEW DATA SUPPORTING COMBINATION OF BEMNIFOSBUVIR AND RUZASVIR AS POTENTIAL BEST-IN-CLASS REGIMEN FOR TREATMENT OF HEPATITIS C VIRUS INFECTION AT THE LIVER MEETING® 2025

07-10-2025
BOSTON, OCT. 07, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY...
Více zde

ATEA PHARMACEUTICALS TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE

02-09-2025
BOSTON, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPAN...
Více zde

ATEA PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07-08-2025
PATIENT ENROLLMENT ADVANCES IN GLOBAL PHASE 3 PROGRAM FOR TREATMENT OF HCV  FOUR SCIENTIFIC POSTERS...
Více zde

ATEA PHARMACEUTICALS TO HOST SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE CONFERENCE CALL ON AUGUST 7, 2025

31-07-2025
BOSTON, JULY 31, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY...
Více zde

ATEA PHARMACEUTICALS ANNOUNCES CONTINUED ADVANCEMENT OF GLOBAL PHASE 3 HCV PROGRAM WITH DOSING OF FIRST PATIENT IN C-FORWARD OUTSIDE NORTH AMERICA

24-06-2025
C-FORWARD IS THE SECOND PHASE 3 TRIAL IN THE GLOBAL HCV DEVELOPMENT PROGRAM; THE FIRST PHASE 3 TRIAL...
Více zde

ATEA PHARMACEUTICALS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

12-05-2025
ENROLLMENT ONGOING IN PHASE 3 C-BEYOND TRIAL FOR TREATMENT OF HCV FULL PHASE 2 RESULTS FOR REGIMEN O...
Více zde

ATEA PHARMACEUTICALS ANNOUNCES FULL RESULTS FROM PHASE 2 STUDY OF REGIMEN OF BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS (HCV) PRESENTED AT EASL CONGRESS 2025

07-05-2025
FULL RESULTS FROM PHASE 2 STUDY CONFIRMED 98% SUSTAINED VIROLOGIC RESPONSE AT 12 WEEKS POST-TREATMEN...
Více zde

ATEA PHARMACEUTICALS TO HOST VIRTUAL HCV KOL PANEL ON MAY 14, 2025

01-05-2025
PANEL TO DISCUSS CURRENT CHALLENGES ENCOUNTERED BY PATIENTS WITH HCV , RESULTS FROM ATEA'S PHASE 2 S...
Více zde

ATEA PHARMACEUTICALS TO PRESENT NEW DATA SHOWCASING POTENTIAL BEST-IN-CLASS REGIMEN OF BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS AT EASL CONGRESS 2025

23-04-2025
BOSTON, APRIL 23, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPAN...
Více zde

ATEA PHARMACEUTICALS APPOINTS HOWARD H. BERMAN TO BOARD OF DIRECTORS AND ANNOUNCES SHARE REPURCHASE PROGRAM

17-04-2025
BOSTON, APRIL 17, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (“ATEA” OR ...
Více zde

ATEA PHARMACEUTICALS ANNOUNCES DOSING OF FIRST PATIENT IN C-BEYOND, PHASE 3 STUDY EVALUATING REGIMEN OF BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS

09-04-2025
REGIMEN HAS POTENTIAL BEST-IN-CLASS PROFILE WITH SHORT TREATMENT DURATION, LOW RISK FOR DRUG-DRUG IN...
Více zde

DRIVER NOTIFIES ATEA PHARMACEUTICALS OF WITHDRAWAL OF NOTICE OF NOMINATION

31-03-2025
STATES CHANGE IN BOARD COMPOSITION SORELY NEEDED EXPRESSES SUPPORT FOR RADOFF-JEC GROUP NOMINEES STA...
Více zde

ATEA PHARMACEUTICALS HIGHLIGHTS ACTIONS UNDERWAY TO ENHANCE SHAREHOLDER VALUE

26-03-2025
BOSTON, MARCH 26, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPAN...
Více zde

THE RADOFF-JEC GROUP NOMINATES THREE HIGHLY QUALIFIED CANDIDATES FOR ELECTION TO THE ATEA PHARMACEUTICALS BOARD OF DIRECTORS

26-03-2025
HOUSTON--(BUSINESS WIRE)--BRADLEY L. RADOFF AND MICHAEL TOROK (TOGETHER WITH CERTAIN OF THEIR AFFILI...
Více zde

ATEA PHARMACEUTICALS ISSUES STATEMENT REGARDING DIRECTOR NOMINATIONS

21-03-2025
BOSTON, MARCH 21, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPAN...
Více zde

ATEA PHARMACEUTICALS ANNOUNCES PRESENTATION OF BEMNIFOSBUVIR PRECLINICAL DATA AT THE 38TH INTERNATIONAL CONFERENCE ON ANTIVIRAL RESEARCH (ICAR) 2025

19-03-2025
BOSTON, MARCH 19, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPAN...
Více zde

ATEA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

06-03-2025
SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA AND ALIGNMENT ON PHASE 3 PROGRAM FOR HEPATITIS C VIRUS ( ...
Více zde

ATEA PHARMACEUTICALS TO HOST FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 6, 2025

27-02-2025
BOSTON, FEB. 27, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (“ATEA”), A ...
Více zde

ATEA PHARMACEUTICALS APPOINTS ARTHUR S. KIRSCH TO BOARD OF DIRECTORS

24-02-2025
BOSTON, FEB. 24, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY...
Více zde

ATEA PHARMACEUTICALS TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

08-01-2025
BOSTON, JAN. 08, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (“ATEA”), A ...
Více zde

CONCERNED SHAREHOLDER GROUP CALLS FOR ATEA PHARMACEUTICALS TO APPOINT A NEW, SHAREHOLDER-ORIENTED LEAD INDEPENDENT DIRECTOR TO OVERSEE STRATEGIC REVIEW PROCESS

18-12-2024
HOUSTON--(BUSINESS WIRE)--BRADLEY L. RADOFF AND MICHAEL TOROK, THE MANAGING DIRECTOR OF JEC CAPITAL ...
Více zde

ATEA PHARMACEUTICALS RETAINS FINANCIAL ADVISOR TO EXPLORE STRATEGIC PARTNERSHIPS

16-12-2024
BOSTON, DEC. 16, 2024 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-08 00:00:008-KStáhnout
2025-11-12 00:00:008-KStáhnout
2025-11-12 00:00:0010-QStáhnout
2025-08-07 01:00:008-KStáhnout
2025-08-07 01:00:0010-QStáhnout
2025-08-07 00:00:008-KStáhnout
2025-08-07 00:00:0010-QStáhnout
2025-06-20 01:00:008-KStáhnout
2025-06-20 00:00:008-KStáhnout
2025-05-12 01:00:008-KStáhnout
2025-05-12 01:00:0010-QStáhnout
2025-05-12 00:00:008-KStáhnout
2025-05-12 00:00:0010-QStáhnout
2025-04-17 01:00:008-KStáhnout
2025-04-17 00:00:008-KStáhnout
2025-04-01 01:00:008-KStáhnout
2025-04-01 00:00:008-KStáhnout
2025-03-24 00:00:008-KStáhnout
2025-03-23 23:00:008-KStáhnout
2025-03-06 00:00:008-KStáhnout
2025-03-06 00:00:0010-KStáhnout
2025-03-05 23:00:008-KStáhnout
2025-03-05 23:00:0010-KStáhnout
2025-02-24 00:00:008-KStáhnout
2025-02-23 23:00:008-KStáhnout
2025-01-14 00:00:008-KStáhnout
2025-01-13 23:00:008-KStáhnout
2024-11-07 00:00:008-KStáhnout
2024-11-07 00:00:0010-QStáhnout
2024-11-06 23:00:008-KStáhnout
2024-11-06 23:00:0010-QStáhnout
2024-08-07 01:00:008-KStáhnout
2024-08-07 01:00:0010-QStáhnout
2024-08-07 00:00:008-KStáhnout
2024-08-07 00:00:0010-QStáhnout
2024-06-21 01:00:008-KStáhnout
2024-06-21 00:00:008-KStáhnout
2024-05-14 01:00:008-KStáhnout
2024-05-14 01:00:0010-QStáhnout
2024-05-14 00:00:008-KStáhnout
2024-05-14 00:00:0010-QStáhnout
2024-02-28 00:00:008-KStáhnout
2024-02-28 00:00:0010-KStáhnout
2024-02-27 23:00:008-KStáhnout
2023-11-08 00:00:008-KStáhnout
2023-11-08 00:00:0010-QStáhnout
2023-11-07 23:00:008-KStáhnout
2023-11-07 23:00:0010-QStáhnout
2023-08-08 01:00:008-KStáhnout
2023-08-08 01:00:0010-QStáhnout
2023-08-08 00:00:008-KStáhnout
2023-08-08 00:00:0010-QStáhnout
2023-06-21 01:00:008-KStáhnout
2023-06-21 00:00:008-KStáhnout
2023-05-08 01:00:008-KStáhnout
2023-05-08 01:00:0010-QStáhnout
2023-05-08 00:00:008-KStáhnout
2023-05-08 00:00:0010-QStáhnout
2023-02-28 00:00:008-KStáhnout
2023-02-28 00:00:0010-KStáhnout
2023-02-27 23:00:008-KStáhnout
2023-02-27 23:00:0010-KStáhnout
2022-11-07 00:00:008-KStáhnout
2022-11-07 00:00:0010-QStáhnout
2022-11-06 23:00:008-KStáhnout
2022-11-06 23:00:0010-QStáhnout
2022-08-08 01:00:008-KStáhnout
2022-08-08 01:00:0010-QStáhnout
2022-08-08 00:00:008-KStáhnout
2022-08-08 00:00:0010-QStáhnout
2022-06-21 01:00:008-KStáhnout
2022-06-21 00:00:008-KStáhnout
2022-05-10 01:00:008-KStáhnout
2022-05-10 01:00:0010-QStáhnout
2022-05-10 00:00:008-KStáhnout
2022-05-10 00:00:0010-QStáhnout
2022-02-28 00:00:008-KStáhnout
2022-02-28 00:00:0010-KStáhnout
2022-02-27 23:00:008-KStáhnout
2022-02-27 23:00:0010-KStáhnout
2022-01-10 00:00:008-KStáhnout
2022-01-09 23:00:008-KStáhnout
2021-11-26 00:00:008-KStáhnout
2021-11-25 23:00:008-KStáhnout
2021-11-16 00:00:008-KStáhnout
2021-11-15 23:00:008-KStáhnout
2021-11-12 00:00:008-KStáhnout
2021-11-12 00:00:0010-QStáhnout
2021-11-11 23:00:008-KStáhnout
2021-11-11 23:00:0010-QStáhnout
2021-08-12 01:00:008-KStáhnout
2021-08-12 01:00:0010-QStáhnout
2021-08-12 00:00:008-KStáhnout
2021-08-12 00:00:0010-QStáhnout
2021-07-23 01:00:008-KStáhnout
2021-07-23 00:00:008-KStáhnout
2021-06-21 01:00:008-KStáhnout
2021-06-21 00:00:008-KStáhnout
2021-05-20 01:00:008-KStáhnout
2021-05-20 00:00:008-KStáhnout
2021-05-13 01:00:008-KStáhnout
2021-05-13 01:00:0010-QStáhnout
2021-05-13 00:00:008-KStáhnout
2021-05-13 00:00:0010-QStáhnout
2021-04-19 01:00:008-KStáhnout
2021-04-19 00:00:008-KStáhnout
2021-03-30 01:00:0010-KStáhnout
2021-03-30 00:00:0010-KStáhnout
2020-12-10 00:00:0010-QStáhnout
2020-12-09 23:00:0010-QStáhnout
2020-11-05 00:00:008-KStáhnout
2020-11-04 23:00:008-KStáhnout
preloader